<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817164</url>
  </required_header>
  <id_info>
    <org_study_id>THY-004</org_study_id>
    <nct_id>NCT03817164</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis</brief_title>
  <official_title>Multicenter, Randomized, Double-Blind, Sham-Controlled, Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thync Global, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ethica Clinical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thync Global, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 16-week, prospective, multicenter, double-blind, controlled, randomized study&#xD;
      assessing change in psoriasis severity and level of stress in patients with moderate&#xD;
      psoriasis treated with ANM. Psoriasis severity and stress levels will be measured at Weeks 0,&#xD;
      2, 8, 12, and 16.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">October 2, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BSA x sPGA average percent change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Body Surface Area x Static Physician Global Assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sPGA change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Static Physician Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSA change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Body Surface Area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PASI change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Psoriasis Area and Severity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI 50</measure>
    <time_frame>Week 16</time_frame>
    <description>Psoriasis Area and Severity Index - 50% reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI 75</measure>
    <time_frame>Week 16</time_frame>
    <description>Psoriasis Area and Severity Index - 75% reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSSI change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Psoriasis Scalp Severity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QVAS change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Stress Level Quantified Visual Analogue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Dermatology Life Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PQOL-12 change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Psoriasis Quality of Life - 12 Item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Hospital Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus NRS change from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Pruritus Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus NRS responder rate (i.e., proportion of subjects achieving a ≥4-point improvement)</measure>
    <time_frame>Week 16</time_frame>
    <description>Pruritus Numerical Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSQM</measure>
    <time_frame>Week 16</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication</description>
  </secondary_outcome>
  <other_outcome>
    <measure>sPGA responder rate (i.e., proportion of subjects achieving sPGA 0 or 1)</measure>
    <time_frame>Week 16</time_frame>
    <description>Static Physician Global Assessment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active stimulation pulsed current delivered over 15 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Active stimulation pulsed current (alternative frequency) delivered over 15 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Autonomic Nerve Modulation - Active</intervention_name>
    <description>Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.</description>
    <arm_group_label>Active Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Autonomic Nerve Modulation - Control</intervention_name>
    <description>Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.</description>
    <arm_group_label>Control Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatient, male or female of any race, 18 years of age or older. This study has no&#xD;
             pregnancy restrictions.&#xD;
&#xD;
          2. BSA* &lt;10% (excluding palms, soles, intertriginous and inverse areas).&#xD;
&#xD;
          3. sPGA* ≥3 (NOTE: sPGA score will be averaged across all lesions as opposed to grading&#xD;
             target lesions).&#xD;
&#xD;
          4. BSA x sPGA ≥12.&#xD;
&#xD;
          5. Subject diagnosed with chronic plaque psoriasis at least 6 months prior to screening.&#xD;
&#xD;
          6. Treatment-naïve of prohibited biological immunomodulating agents at the time of&#xD;
             screening, or decided to stop treatment with the biologic before screening for the&#xD;
             study.&#xD;
&#xD;
          7. Be able to follow study instructions and likely to complete all required visits.&#xD;
&#xD;
          8. Sign the IRB-approved ICF (which includes HIPAA).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-plaque psoriasis (erythrodermic or pustular), guttate, inverse psoriatic&#xD;
             arthritis, or drug-induced psoriasis.&#xD;
&#xD;
          2. Subjects with plaque psoriasis on palms and soles at enrolment.&#xD;
&#xD;
          3. Subjects with plaque psoriasis on the back of the neck that would interfere with&#xD;
             device placement.&#xD;
&#xD;
          4. Evidence of skin conditions other than psoriasis that would interfere with&#xD;
             study-related evaluations of psoriasis.&#xD;
&#xD;
          5. Other than psoriasis, history of any clinically significant (as determined by&#xD;
             Investigator) or other major uncontrolled disease.&#xD;
&#xD;
          6. Psoriasis flare or rebound within 4 weeks of Visit 1 or spontaneously improving or&#xD;
             rapidly deteriorating plaque psoriasis during that same time period, as determined by&#xD;
             investigator.&#xD;
&#xD;
          7. Use of prohibited medications within the following washout periods:&#xD;
&#xD;
               -  Biological immunomodulating agents within the prior 12 weeks: etanercept&#xD;
                  (Enbrel), adalimumab (Humira), infliximab (Remicade), certolizumab pegol&#xD;
                  (Cimzia), ixekizumab (Taltz)&#xD;
&#xD;
               -  Biological immunomodulating agents within the prior 24 weeks: ustekinumab&#xD;
                  (Stelara), secukinumab (Cosentyx), guselkumba (Tremfaya)&#xD;
&#xD;
               -  Oral drugs within the prior 4 weeks: apremilast, methotrexate, cyclosporine,&#xD;
                  corticosteroids&#xD;
&#xD;
               -  Oral drugs within the prior 12 weeks: acitretin&#xD;
&#xD;
               -  Photochemotherapy (PUVA) within the prior 4 weeks&#xD;
&#xD;
               -  Phototherapy (UVA/UVB) within the prior 2 weeks&#xD;
&#xD;
               -  Topical treatment likely to impact signs and symptoms of psoriasis (e.g.,&#xD;
                  corticosteroids, vitamin D analogues, retinoids, calcineurin inhibitors,&#xD;
                  salicylic acid, lactic acid, tar, urea, etc.) within the prior 2 weeks&#xD;
&#xD;
          8. Prolonged sun exposure or use of tanning booths or other source of UV radiation.&#xD;
&#xD;
          9. Medical or psychiatric conditions that may increase the risk associated with study&#xD;
             participation or may interfere with the interpretation of study results or compliance&#xD;
             of the subject and, in the opinion of the PI, would make the subject inappropriate for&#xD;
             entry into this study.&#xD;
&#xD;
         10. Clinically significant alcohol or drug abuse, or history of poor cooperation or&#xD;
             unreliability.&#xD;
&#xD;
         11. Exposure to any other investigational drug/device within 30 days prior to study entry.&#xD;
&#xD;
         12. Subjects with a pacemaker, or any type of metal implant in the neck (i.e., T5 and&#xD;
             above).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

